Jeronselvain to Deliver Special PDRN Lecture at 'ASLS Indonesia 2024'

Specialized pharmaceutical manufacturer Jeron Selvein announced on the 28th that it successfully completed its exhibition and lecture at 'ASLS Indonesia 2024,' held at the Pullman Jakarta Central Park Hotel in Indonesia.

At this conference, Jeron Selvein operated a lecture session and a solo exhibition booth focusing on the prescription drug 'Selveinju,' a pain and inflammation treatment based on polynucleotide (PDRN), and the export filler 'Cledence,' which contains PN (Polynucleotide), attracting significant interest and attention, according to the company.

Selveinju is based on PDRN extracted from the germ cells of chum salmon and, unlike conventional analgesics or steroid preparations, it is effective in tissue regeneration through anti-inflammatory effects and immune cell activation. It is characterized by a strong cell regeneration effect due to a consistent low molecular size PDRN manufactured using Jeron Selvein’s patented Prism Technology (Prism-T).

ASLS (Aesthetic Surgery & Laser Society) is a society organized by the Korean Society of Aesthetic Plastic Surgery and Laser Medicine (Daemire) for academic exchange among medical professionals and industry stakeholders worldwide in the fields of aesthetics and plastic surgery. This conference, the ASLS & PERDAWERI BANTEN International Academic Conference in Jakarta, Indonesia, featured world-class speakers from Korea and Indonesia sharing technology, expertise, and knowledge in aesthetic medicine.

Kim Deokgyu, CEO of Jeron Selvein, stated, “Through this ASLS conference, we introduced the efficient and safe treatment methods and efficacy of Selveinju and Cledence, strengthening our network with local medical professionals. It was an honorable opportunity to supply our products to more hospitals and to showcase the excellence of our products.”

He added, “We will continue to solidify our position in the medical and beauty markets through ongoing participation in domestic and international conferences and exhibitions. We will strive to increase our market share and corporate value in the Indonesian market.”